Genesis
12 hours ago
ML Research Intern, PhD - 2026
Job Description
About the Team
Join a world-class team at the forefront of AI and biochemistry.
At Genesis Therapeutics, we’re a tight-knit team of proven deep learning researchers, software engineers, and drug discovery pioneers. Our shared mission is nothing short of revolutionary: to forge the next generation of AI foundation models that will unlock groundbreaking therapies for patients with severe diseases.
We don’t just apply machine learning to biology; we are conducting fundamental research at the intersection of machine learning, physics, and computational chemistry, pushing the boundaries of each field. You will work side-by-side with top multidisciplinary researchers to design and build generative foundation models at scale, having access to ample compute and large-scale simulations.
About the Role
This is an opportunity to operate as a full member of our research team and to drive forward our ML research agenda for generative modeling of molecular systems. You will be paired with a mentor to work on a high-impact research project at the frontier of generative AI. Your work will likely involve making advancements to novel foundation models, with potential projects in areas like diffusion models, large language models (LLMs), reinforcement learning (RL), and multi-modal learning. We’re looking for exceptional PhD candidates passionate about conducting novel research that contributes directly to our mission of discovering new medicines.
You Will
You Are
What we offer
Genesis Therapeutics is unifying AI and biotech to discover novel and breakthrough treatments for patients with severe and devastating conditions. Genesis was founded on groundbreaking molecular ML research and since has established itself as the industry leader in AI for small molecule drug discovery. Our team of accomplished biotech leaders and expert drug hunters joins forces with deep learning researchers and software engineers who are pioneering predictive and generative AI technologies for molecules.
Our team has created the industry's most advanced molecular AI platform called GEMS (Genesis Exploration of Molecular Space), to accelerate and optimize small molecule drug discovery and to enable the discovery of novel first-in-class and best-in-class small molecule drugs for challenging and/or undruggable targets.
The company has leveraged GEMS to build an internal pipeline with multiple programs against high-value targets, including data-poor and canonically undruggable targets where GEMS is uniquely advantaged. In addition, Genesis has signed AI-focused platform collaborations with major pharmaceutical companies, including most recently Incyte Corporation (Feb 2025) and Gilead Sciences (Sept 2024).
We raised a $200M series B in August 2023, and have raised over $300M in funding from top technology and biotech investors, including Andreessen Horowitz, Rock Springs Capital, T. Rowe Price, Fidelity, Radical Ventures, NVentures (NVIDIA's VC arm), BlackRock, and Menlo Ventures.
Genesis is headquartered in Burlingame, CA, with a fully integrated laboratory in San Diego. We are proud to be an inclusive workplace and an Equal Opportunity Employer.
